Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IORT and Bevacizumab for Recurrent Glioblastoma
NCT04681677Phase 2Terminated
- Sponsor
- Xoft
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Xoft. Primary endpoint: median overall survival at 3 years. Started Nov 2021; status: terminated.
Beyond the preview
Go deeper on NCT04681677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681677.